This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Improving prediction accuracy in acute myeloid leukaemia: micro-environment, immune and metabolic models
Leukemia Open Access 07 August 2021
-
A small molecule inhibitor of mutant IDH2 rescues cardiomyopathy in a D‐2‐hydroxyglutaric aciduria type II mouse model
Journal of Inherited Metabolic Disease Open Access 28 July 2016
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009; 462: 739–744.
Gross S, Cairns RA, Minden MD, Driggers EM, Bittinger MA, Jang HG et al. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Exp Med 2010; 207: 339–344.
DiNardo CD, Propert KJ, Loren AW, Paietta E, Sun Z, Levine RL et al. Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia. Blood 2013; 121: 4917–4924.
Janin M, Mylonas E, Saada V, Micol JB, Renneville A, Quivoron C et al. Serum 2-hydroxyglutarate production in IDH1- and IDH2-mutated de novo acute myeloid leukemia: a study by the Acute Leukemia French Association Group. J Clin Oncol 2014; 32: 297–305.
Losman JA, Kaelin WG . What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes Dev 2013; 27: 836–852.
Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010; 18: 553–567.
Lu C, Venneti S, Akalin A, Fang F, Ward PS, Dematteo RG et al. Induction of sarcomas by mutant IDH2. Genes Dev 2013; 27: 1986–1998.
Rohle D, Popovici-Muller J, Palaskas N, Turcan S, Grommes C, Campos C et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science 2013; 340: 626–630.
Losman JA, Looper RE, Koivunen P, Lee S, Schneider RK, McMahon C et al. (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science 2013; 339: 1621–1625.
Wang F, Travins J, DeLaBarre B, Penard-Lacronique V, Schalm S, Hansen E et al. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science 2013; 340: 622–626.
Sasaki M, Knobbe CB, Munger JC, Lind EF, Brenner D, Brustle A et al. IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics. Nature 2012; 488: 656–659.
Chen C, Liu Y, Lu C, Cross JR, Morris JP 4th, Shroff AS et al. Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibition. Genes Dev 2013; 27: 1974–1985.
Chaturvedi A, Araujo Cruz MM, Jyotsana N, Sharma A, Yun H, Gorlich K et al. Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML. Blood 2013; 122: 2877–2887.
Cairns RA, Iqbal J, Lemonnier F, Kucuk C, de Leval L, Jais JP et al. IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma. Blood 2012; 119: 1901–1903.
Acknowledgements
We thank Jacques Bosq for thoughtful discussions, Philippe Rameau (PFIC, Institut Gustave Roussy, Villejuif, France) for cell-sorting cytometry, mice facility staff (Institut Gustave Roussy, Villejuif, France) and Audrey Joffrain for technical assistance. This work was supported by grants from INSERM, the Institut National du Cancer (INCa), the Cancéropôle Ile de France and the Association Laurette Fugain. MD is funded by a fellowship from the INCa (INCa-DGOS_5733).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Author contributions
EM, OAB, CO, SDB and VPL designed research, analyzed data and wrote the manuscript. MJ performed the dosage of 2-HG. OB and PO carried out the histological analysis. MD and CQ performed the measure of 5mC and 5hmC content. All the authors read and approved the manuscript.
Supplementary Information accompanies this paper on the Leukemia website
Rights and permissions
About this article
Cite this article
Mylonas, E., Janin, M., Bawa, O. et al. Isocitrate dehydrogenase (IDH)2 R140Q mutation induces myeloid and lymphoid neoplasms in mice. Leukemia 28, 1343–1346 (2014). https://doi.org/10.1038/leu.2014.18
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2014.18
This article is cited by
-
Improving prediction accuracy in acute myeloid leukaemia: micro-environment, immune and metabolic models
Leukemia (2021)
-
The Non-canonical Role of Metabolic Enzymes in Immune Cells and Its Impact on Diseases
Current Tissue Microenvironment Reports (2020)
-
A small molecule inhibitor of mutant IDH2 rescues cardiomyopathy in a D‐2‐hydroxyglutaric aciduria type II mouse model
Journal of Inherited Metabolic Disease (2016)
-
Clinical and biological implications of ancestral and non-ancestral IDH1 and IDH2 mutations in myeloid neoplasms
Leukemia (2015)
-
The mechanistic role of DNA methylation in myeloid leukemogenesis
Leukemia (2014)